Assistant Professor, Harvard Medical School, Boston MA Director, Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Boston MA Associate Member, Broad Institute
The chromatin regulators CBP and p300 maintain gene expression programs through lysine acetylation of chromatin and transcriptional regulators and by scaffolding functions mediated by several protein-protein interaction domains. We have developed a chemical degrader of p300/CBP, dCBP-1, using in silico modeling and cellular activity assays including capillary-based immunodetection assays (ProteinSimple, WES). We have found that dCBP-1 is exceptionally potent at killing multiple myeloma cells and can abolish the enhancer that drive MYC oncogene expression. As an efficient degrader of this unique class of chromatin regulators, dCBP-1 will be a useful tool for understanding p300/CBP activity at enhancers in both normal and diseased cells.
Webinars will be available for unlimited on-demand viewing after live event.
Join this year's poster presenters in the Poster Hall during the Poster Networking Hour, Wednesday, September 20th, from 10:00 AM –11:00 AM PDT , to chat live about their posters a...
Routine coagulation assays are widely performed in laboratories and provide valuable information to the patient’s overall clinical picture. It’s important for laboratorians to kn...
Quality efforts in the clinical laboratory are always under the microscope- a hyper-focus for laboratorians from start to finish. Recognizing the external factors that affect hemostasis test...
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
Loading Comments...
Please update your information
Certificate of Attendance
Thank you for choosing Labroots. Please note that a Certificate of Attendance does NOT count towards Continuing Education Credits.